Highest-materiality recent filing
Definitive Healthcare shareholders approve 15M share increase under 2021 equity plan
Amendment to 2021 Equity Incentive Plan approved: shares authorized increase from 30.97M to 45.97M (15M new shares).
Definitive Healthcare Q1 revenue $55.9M (-6% YoY); net loss $192.4M on $197M goodwill impairment
Revenue of $55.9M, at top end of guidance, down 6% from $59.2M in Q1 2025.
Definitive Healthcare terminates nominating agreement with Spectrum; designee resigned
Spectrum had right to designate one director nominee while holding ≥5% of outstanding shares.
Definitive Healthcare director Jeff Haywood resigns from Board and Compensation Committee
Jeff Haywood resigned from the Board and Compensation Committee effective March 30, 2026.
Q4 revenue $61.5M vs $62.3M prior year; adjusted EBITDA $18.0M (29% margin) vs $17.5M (28%).
Definitive Healthcare Q3 revenue $60M (-4% YoY); net loss $17.8M; raises FY revenue guidance low end
Revenue $60.0M (-4% vs $62.7M in Q3 2024); net loss $17.8M (vs $187.8M including $228.2M goodwill impairment).
Definitive Healthcare Q2 revenue $60.8M (-5% YoY); raises FY revenue guidance bottom by $3M
Q2 net loss $(9.3)M vs $(306.2)M (prior year included $363.6M goodwill impairment).
Jill Larsen resigned from the Board and as Chair of the Human Capital Management and Compensation Committee effective July 21, 2025.
Definitive Healthcare eliminates COO role; Shamsuddin Jensen to depart Aug 1, 2025
COO position eliminated; Kate Shamsuddin Jensen will remain employed through August 1, 2025.
Definitive Healthcare stockholders elect three Class I directors, ratify auditor, approve say-on-pay
Kevin Coop, Jason Krantz, and Lauren Young elected Class I directors with 118M, 117M, and 108M votes for, respectively.
Revenue $59.2M, down 7% YoY; net loss $155.1M including $176.5M goodwill impairment.
Definitive Healthcare Q4 revenue $62.3M (-6% YoY); guides FY2025 $230-240M; names Casey Heller CFO
Q4 revenue $62.3M, -6% YoY; net loss $(84.7)M including $97.1M goodwill impairment.
Definitive Healthcare enters $175M term loan and $50M revolver, maturing Jan 2030
New $175M term loan facility and $50M revolving credit facility with Bank of America as agent; matures January 16, 2030.
Q3 revenue $62.7M, down 4% YoY; net loss $(187.8)M includes $228.2M goodwill impairment; adjusted EBITDA $20.6M (33% margin).
Definitive Healthcare promotes Kate Shamsuddin Jensen to COO effective Oct 1
Ms. Shamsuddin Jensen, previously Chief Strategy Officer, named Chief Operating Officer.
Definitive Healthcare Q2 revenue $63.7M (+5% YoY); net loss $(306.2)M on $363.6M goodwill impairment
Revenue $63.7M (+5% YoY); net loss $(306.2)M including $363.6M goodwill impairment (up 2,538% from $(11.6)M).
Definitive Healthcare Q2 prelim revenue $63.7M (+5% YoY), goodwill impairment $363.6M; CRO resigns
Revenue $63.7M (+5% YoY); adjusted EBITDA $20.9M (33% margin) vs $17.2M (28%) YoY.
Definitive Healthcare grants CEO Kevin Coop 186,192 RSUs as make-whole award
RSU award granted July 4, 2024 to compensate for equity grant shortfall due to share price volatility.
Appoints Kevin Coop as CEO effective June 24; Founder Krantz remains Executive Chairman
Kevin Coop appointed CEO effective June 24, 2024; founder Jason Krantz steps down as interim CEO but stays as Executive Chairman.
Definitive Healthcare Q1 revenue $63.5M (+7% YoY); Adj. EBITDA margin 32%; $20M buyback
Revenue $63.5M, +7% YoY from $59.2M; net loss narrowed to $12.7M from $16.0M.
Q4 revenue $65.9M (+9% YoY); FY23 revenue $251.4M (+13% YoY).
The Company previously announced that Richard Booth, the Company’s current CFO, would be departing the Company effective June 1, 2025.
On February 24, 2025, the Board of Directors (the “Board”) of the Company appointed Casey Heller to the position of Chief Financial Officer (“CFO”) effective June 2, 2025.
Richard Booth, the Company’s Chief Financial Officer, and the Company agreed that Mr. Booth will be leaving the Company effective June 1, 2025.
On September 29, 2024, the Board of Directors (the “Board”) of Definitive Healthcare Corp. (the “Company”) promoted Kate Shamsuddin Jensen, the Company’s current Chief Strategy Officer, to the role of Chief Operating Officer, effective as of October 1, 2024 (the “Effective Date”).
On July 24, 2024, Carrie Lazorchak, the Chief Revenue Officer of the Company, provided the Company with notice of her resignation, effective August 2, 2024.
On May 20, 2024, the Board of Directors (the “Board”) of Definitive Healthcare Corp. (the “Company”) appointed Kevin Coop to the position of Chief Executive Officer (“CEO”) and as a member of the Board, each effective June 24, 2024 (the “Start Date”).
Effective on the Start Date, Jason Krantz, the Company’s founder, Executive Chairman of the Board and current Interim CEO will step down from his role as Interim CEO and continue to serve as Executive Chairman of the Board.
Max materiality 0.80 · Median 0.65 · Most common event earnings